Vasodilators such as ACEIs, ARBs, calcium antagonists (CCBs), and nitrates are commonly used in cardiovascular diseases and have good therapeutic effects; PDE-5 inhibitors, nitric oxide (NO), prostacyclins, and endothelin receptor antagonists are commonly used in patients with pulmonary arterial hypertension (PH); however, the effects of these drugs on ventilation and expiratory function in COPD are not yet known. The gene discussed is PDE5A; the disease is chronic obstructive pulmonary disease.